Chronic lymphocytic leukaemia (CLL) is an indolent B-cell malignancy that has a strong genetic component, as evidenced by the eightfold increased risk seen in relatives of CLL patients[@b1]. Our understanding of CLL genetics has been transformed by genome-wide association studies (GWAS) that have identified risk alleles for CLL[@b2][@b3][@b4][@b5][@b6][@b7][@b8][@b9]. So far, common genetic variation at 33 loci has been shown to influence CLL risk. Although projections indicate that additional risk variants for CLL can be discovered by GWAS, the statistical power of the individual existing studies is limited.

To gain a more comprehensive insight into CLL predisposition, we analysed genome-wide association data from populations of European ancestry from Europe, North America and Australia, identifying nine new risk loci. Our findings provide additional insights into the genetic and biological basis of CLL risk.

Results
=======

Association analysis
--------------------

After quality control, the six GWAS provided single-nucleotide polymorphism (SNP) genotypes on 4,478 cases and 13,213 controls ([Supplementary Tables 1 and 2](#S1){ref-type="supplementary-material"}). To increase genomic resolution, we imputed \>10 million SNPs using the 1000 Genomes Project[@b10] combined with UK10K[@b11] as reference. Quantile--Quantile (Q--Q) plots for SNPs with minor allele frequency (MAF) \>0.5% post imputation did not show evidence of substantive overdispersion (*λ* between 1.00 and 1.10 across the studies; [Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). Meta-analysing the association test results from the six series, we derived joint odds ratios per-allele and 95% confidence intervals under a fixed-effects model for each SNP and associated *P* values. In this analysis, associations for the established risk loci were consistent in direction and magnitude of effect with previously reported studies ([Fig. 1](#f1){ref-type="fig"} and [Supplementary Table 3](#S1){ref-type="supplementary-material"}).

We identified 16 loci where at least one SNP showed evidence of association with CLL (defined as *P*\<1.0 × 10^−7^ in fixed-effects meta-analysis of the six series) and which were not previously implicated with CLL risk at genome-wide significance (that is, *P*\<5.0 × 10^−8^; [Table 1](#t1){ref-type="table"} and [Supplementary Tables 4 and 5](#S1){ref-type="supplementary-material"}). Where the signal was provided by an imputed SNP, we confirmed the fidelity of imputation by genotyping ([Supplementary Table 6](#S1){ref-type="supplementary-material"}). We substantiated the 16 SNPs using *de novo* genotyping in two studies and *in silico* replication in two additional studies, totalling 1,722 cases and 4,385 controls. Meta-analysis of the discovery and replication studies revealed genome-wide significant associations for eight novel loci ([Table 1](#t1){ref-type="table"}) at 1p36.11 (rs34676223, *P*=5.04 × 10^−13^), 1q42.13 (rs41271473, *P*=1.06 × 10^−10^), 4q35.1 (rs57214277, *P*=3.69 × 10^−8^), 6p21.31 (rs3800461, *P*=1.97 × 10^−8^), 11q23.2 (rs61904987, *P*=2.64 × 10^−11^), 18q21.1 (rs1036935, *P*=3.27 × 10^−8^), 19p13.3 (rs7254272, *P*=4.67 × 10^−8^) and 22q13.33 (rs140522, *P*=2.70 × 10^−9^). We also confirmed 4q24 (rs71597109, *P*=1.37 × 10^−10^), which has previously been identified as a suggestive risk locus[@b9]. Conditional analysis of GWAS data showed no evidence for additional independent signals at these nine loci. In the remaining seven loci that did not replicate with genome-wide significance, the 9q22.33 locus (rs7026022, *P*=7.00 × 10^−8^) remains suggestive ([Supplementary Table 5](#S1){ref-type="supplementary-material"}). In analyses limited to the exomes of 141 CLL cases from 66 families, we found no evidence to suggest that any of the association signals might be a consequence of linkage disequilibrium (LD) with a rare disruptive coding variant.

Several of the newly identified risk SNPs map in or near to genes with established roles in B-cell biology, hence representing credible candidates for susceptibility to CLL. The 4q24 association marked by rs71597109 ([Fig. 2](#f2){ref-type="fig"}) maps to intron 1 of the gene encoding BANK1 (B-cell scaffold protein with ankyrin repeats 1), a B-cell-specific scaffold protein. SNPs at this locus have been associated with systemic lupus erythematosus risk[@b12]. *BANK1* expression is only seen in functional B-cell antigen receptor (BCR)-expressing B cells, mediating effects through LYN-mediated tyrosine phosphorylation of inositol triphosphate receptors. *BANK1*-deficient mice display higher levels of mature B cells and spontaneous germinal centre B cells[@b13], while studies in humans found lower *BANK1* transcript levels in CLL versus normal B cells[@b14]. The 19p13.3 association marked by rs7254272 ([Fig. 2](#f2){ref-type="fig"}) maps 2.5 kb 5′ to *ZBTB7A* (zinc finger and BTB domain-containing protein 7a, alias *LRF*, leukaemia/lymphoma-related factor, pokemon). ZBTB7A is a master regulator of B versus T lymphoid fate. Loss of *ZBTB7A* results in aberrant activation of the NOTCH pathway in lymphoid progenitors. NOTCH is constitutively activated in CLL and is a determinant of resistance to apoptosis in CLL cells. rs34676223 at 1p36.11 maps ∼10 kb upstream of *MDS2* ([Fig. 2](#f2){ref-type="fig"}), which is the fusion partner of ETV6 in t(1;12)(p36;p13) myelodysplasia. Based on RNA sequencing (RNA-seq) data from patients, *MDS2* is overexpressed in CLL versus normal cells and also differentially expressed between two experimentally determined CLL subgroups[@b14]. The SNP rs57214277 maps to 4q35.1 and resides ∼140 kb centromeric to *IRF2* (interferon regulatory factor 2, [Fig. 2](#f2){ref-type="fig"}). Interferon (IFN)-αβ, a family of antiviral immune genes, induces IRF2 that inhibits the reactivation of murine gamma herpesvirus[@b15]. Furthermore, SNPs in strong LD with rs57214277 are associated with increased expression of *IRF2* as well as *trans*-regulation of a network of genes in lipopolysaccharide and IFNγ-treated monocytes[@b16]. rs140522 maps to 22q13.33 ([Fig. 2](#f2){ref-type="fig"}), which has previously been associated with multiple sclerosis risk[@b17]. This region of LD contains four genes, of which only *NCAPH2* (non-SMC condensin II complex subunit H2) shows differential expression between CLL and normal B cells[@b14] (∼2.5-fold lower levels in CLL), and plays an essential role in mitotic chromosome assembly and segregation. rs41271473, rs3800461, rs61904987 and rs1036935 mark genes that have roles in WNT signalling (*RHOU*), autophagy (*C6orf106*), transcriptional activation (*CXXC1*), kinetochore association (*SKA1*, *ZW10*) and protein degradation (*USP28*, *TMPRSS5*; [Fig. 3](#f3){ref-type="fig"}).

New CLL risk SNPs and clinical phenotype
----------------------------------------

We tested for differences in the associations by sex or age at diagnosis for each of the nine risk SNPs using case-only analysis, and observed no relationships ([Supplementary Data 1](#S1){ref-type="supplementary-material"}). In addition, case-only analysis in a subset of studies provided no evidence for associations between risk SNP genotypes and *IGVH* (immunoglobulin variable region heavy chain) mutation subtype ([Supplementary Data 1](#S1){ref-type="supplementary-material"}) or overall patient survival ([Supplementary Table 7](#S1){ref-type="supplementary-material"}). Collectively, these data suggest that these nine risk variants have generic effects on CLL development rather than tumour progression *per se*.

Functional annotation of new risk loci
--------------------------------------

To gain insight into the biological basis underlying the novel association signals, we first evaluated profiles for three histone marks (H3K4me1, H3K27ac marking active chromatin and the repressive mark H3K27me3) at each locus, in GM12878 lymphoblastoid cell line (LCL; ref. [@b18]) as well as primary CLL samples[@b19] ([Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). We also examined ATAC-seq profiles from CLL samples and primary B cells as a marker of chromatin accessibility[@b19][@b20]. Since the strongest associated GWAS SNP may not represent the causal variant, we examined signals across an interval spanning all variants in LD *r*^2^\>0.2 with the sentinel SNP (based on the 1000 Genomes EUR reference panel). These data revealed regions of active chromatin state at all nine risk loci, in at least one of the cell types. Furthermore, based on the analyses of Hnisz *et al*.[@b21], five of the loci fall within regions designated as 'super enhancers\' in either LCLs or CD19 B cells ([Supplementary Fig. 2](#S1){ref-type="supplementary-material"}). Overall, these findings suggest that the risk loci annotate regulatory regions and may, therefore, have an impact on CLL risk through modulation of enhancer or promoter activity.

Given the possibility that SNPs might influence enhancer or promoter activity by causing changes in transcription factor (TF) binding, we next evaluated the SNPs at each GWAS locus based on their overlap with TF-binding sites. In the absence of comprehensive TF chromatin immunoprecipitation sequencing (ChIP-Seq) data from CLL samples, we used regions of chromatin accessibility defined by ATAC-seq data[@b19] as a surrogate marker for TF binding, identifying 47 SNPs in LD *r*^2^\>0.2 with the sentinel SNPs that also overlapped ATAC-seq peaks. Using motifbreakR[@b22] to predict whether these SNPs might disrupt TF-binding motifs, we found 478 potentially disrupted motifs, corresponding to 349 TF-binding sites ([Supplementary Table 7](#S1){ref-type="supplementary-material"}). Moreover, at 10 of the SNPs, the altered motif matched the TFs bound in ChIP-seq data from the ENCODE project ([Supplementary Table 8](#S1){ref-type="supplementary-material"} and [Supplementary Fig. 3](#S1){ref-type="supplementary-material"}). In particular, we noted that rs13149699 at 4q35 (*r*^2^=0.83 with lead SNP rs57214277) was predicted to disrupt SPI1 binding. In addition, rs13149699 showed evidence of evolutionary constraint, and in LCL ChIP-seq data, the SNP was bound by SPI1 as well as other TFs with roles in B-cell function including IRF4, PAX5, POU2F2 (alias OCT2) and RELA ([Supplementary Table 8](#S1){ref-type="supplementary-material"}).

We explored whether there was any association between the genotypes of the nine new risk SNPs and the transcript levels of genes within 1 Mb of each respective variant by performing expression quantitative trait loci (eQTL) analysis using gene expression profiles of 468 CLL cases. In addition, we interrogated publicly accessible expression data on whole blood and LCLs ([Supplementary Data 2](#S1){ref-type="supplementary-material"}). There were significant (false discovery rate (FDR)\<0.05) and consistent eQTLs between rs3800461 and *C6orf106*, rs1036935 and *SKA1*, rs140522 and *ODF3B*, and rs140522 and *TYMP.*

Biological inference of all CLL risk loci
-----------------------------------------

Given our observation that the nine novel risk loci annotate putative regulatory regions, we sought to examine the epigenetic landscape of CLL risk loci on a broader scale, evaluating the enrichment of both histone modifications (*N*=11) and TF binding (*N*=82) in GM12878 LCLs, across the new and previously published CLL GWAS risk SNPs. Using the variant set enrichment method of Cowper-Sal lari *et al*.[@b23], we identified regions of strong LD (defined as *r*^2^\>0.8 and *D*′\>0.8) and determined the overlap between these variants and ENCODE ChIP-seq data. Imposing a *P* value threshold of 5.37 × 10^−4^ (that is, 0.05/93, based on permutation), we identified a significant enrichment of histone marks associated with active enhancer and promoter elements (HK4Me1, H3K27ac and H3K9ac) as well as actively transcribed regions (H3K36me3). We also identified an over-representation of TF binding for POLR2A, IRF4, RUNX3, NFATC1, STAT5A, PML and WRNIP1 ([Fig. 4](#f4){ref-type="fig"}). In addition, although not statistically significant, POU2F2 showed evidence for enriched binding (*P*=7.78 × 10^−4^). Several of these TFs have established roles in B-cell function. OCT2, IRF4 and RUNX3 have been shown to be targeted for hypomethylation in B cells[@b24]. MYC is a direct target of IRF4 in activated B cells, with IRF4 being itself a direct target of MYC transactivation. It is noteworthy that variations at IRF4 and 8q24-MYC are recognized risk factors for CLL[@b2][@b3]. Collectively, these findings are consistent with CLL GWAS SNPs mapping within regions of active chromatin state that exert effects on B-cell *cis*-regulatory networks.

We investigated the genetic pathways between the gene products in proximity to the GWAS SNPs using the LENS pathway tool[@b25]. These gene products were primarily involved in immune response, BCR-mediated signalling, apoptosis and maintenance of chromosome integrity, as well as interconnectivity between the gene products ([Fig. 5](#f5){ref-type="fig"}). Pathways that were enriched included those related to interferon signalling and apoptosis ([Supplementary Data 3](#S1){ref-type="supplementary-material"}).

Impact of risk SNPs on heritability of CLL
------------------------------------------

By fitting all SNPs from GWAS simultaneously using Genome-wide Complex Trait Analysis, the estimated heritability of CLL attributable to all common variation is 34% (±5%), thus having potential to explain 57% of the overall familial risk. This estimate represents the additive variance and, therefore, does not include the potential impact of interactions or dominance effects or gene--environment interactions, having an impact on CLL risk. The currently identified risk SNPs (newly discovered and previously identified) only account for 25% of the additive heritable risk.

Discussion
==========

Besides providing additional evidence for genetic susceptibility to CLL, the new and established risk loci identified further insights into the biological basis of CLL development. These loci annotate genes that participate in interconnecting cellular pathways, which are central to B-cell development. In particular, we note the involvement of BCR-mediated signalling with immune responses and apoptosis. Importantly, gene discovery initiatives can have an impact on the successful development of new therapeutic agents[@b26]. In this respect it is notable that Ibrutinib[@b27] (a BTK inhibitor) and Idelalisib[@b28] (a PI3KCD inhibitor) mediate their effects through interference of BCR signalling, and Venetoclax[@b29] targets the anti-apoptotic behaviour of BCL-2. The power of our GWAS to identify common alleles conferring relative risks of 1.2 or greater (such as the rs35923643 variant) is high (∼80%). Hence, there are unlikely to be many additional SNPs with similar effects for alleles with frequencies greater than 0.2 in populations of European ancestry. In contrast, our analysis had limited power to detect alleles with smaller effects and/or MAF\<0.1. Hence, further GWAS studies in concert with functional analyses should lead to additional insights into CLL biology and afford the prospect of development of novel therapies.

Methods
=======

Ethics
------

Collection of patient samples and associated clinicopathological information was undertaken with written informed consent and relevant ethical review board approval at respective study centres in accordance with the tenets of the Declaration of Helsinki. Specifically, these centres are UK-CLL1 and UK-CLL2: UK Multi-Research Ethics Committee (MREC 99/1/082); GEC: Mayo Clinic Institutional Review Board, Duke University Institutional Review Board, University of Utah, University of Texas MD Anderson Cancer Center Institutional Review Board, National Cancer Institute, ATBC: NCI Special Studies Institutional Review Board, BCCA: UBC BC Cancer Agency Research Ethics Board, CPS-II: American Cancer Society, ENGELA: IRB00003888---Comite d\' Evaluation Ethique de l\'Inserm IRB \#1, EPIC: Imperial College London, EpiLymph: International Agency for Research on Cancer, HPFS: Harvard School of Public Health (HSPH) Institutional Review Board, Iowa-Mayo SPORE: University of Iowa Institutional Review Board, Italian GxE: Comitato Etico Azienda Ospedaliero Universitaria di Cagliari, Mayo Clinic Case--Control: Mayo Clinic Institutional Review Board, MCCS: Cancer Council Victoria\'s Human Research Ethics Committee, MSKCC: Memorial Sloan-Kettering Cancer Center Institutional Review Board, NCI-SEER (NCI Special Studies Institutional Review Board), NHS: Partners Human Research Committee, Brigham and Women\'s Hospital, NSW: NSW Cancer Council Ethics Committee, NYU-WHS: New York University School of Medicine Institutional Review Board, PLCO: (NCI Special Studies Institutional Review Board), SCALE: Scientific Ethics Committee for the Capital Region of Denmark, SCALE: Regional Ethical Review Board in Stockholm (Section 4) IRB\#5, Utah: University of Utah Institutional Review Board, UCSF and UCSF2: University of California San Francisco Committee on Human Research, Women\'s Health Initiative (WHI): Fred Hutchinson Cancer Research Center and Yale: Human Investigation Committee, Yale University School of Medicine. Informed consent was obtained from all participants. The diagnosis of CLL (ICD-10-CM C91.10, ICD-O M9823/3 and 9670/3) was established in accordance with the International Workshop on Chronic Lymphocytic Leukemia guidelines[@b30].

Genome-wide association studies
-------------------------------

The meta-analysis was based on six GWAS[@b2][@b6][@b7][@b9] ([Supplementary Tables 1 and 2](#S1){ref-type="supplementary-material"}). Briefly, the six GWAS comprised---UK-CLL1: 517 CLL cases and 2,698 controls; UK-CLL2: 1,403 CLL cases, 2,501 controls; Genetic Epidemiology of CLL (GEC) Consortium: 396 CLL cases and 296 controls; NHL GWAS Consortium: 1,851 CLL cases and 6,649 controls; UCSF: 214 CLL cases, 751 controls; Utah: 331 CLL cases, 420 controls.

Quality control of GWAS
-----------------------

Standard quality-control measures were applied to the GWAS[@b31]. Specifically, individuals with low call rate (\<95%) as well as all individuals evaluated to be of non-European ancestry (using the HapMap version 2 CEU, JPT/CHB and YRI populations as a reference) were excluded. For apparent first-degree relative pairs, we removed the control from a case--control pair; otherwise, we excluded the individual with the lower call rate. SNPs with a call rate \<95% were excluded as were those with a MAF \<0.01 or displaying significant deviation from Hardy--Weinberg equilibrium (that is, *P*\<10^−6^). GWAS data were imputed to \>10 million SNPs with the IMPUTE2 v2.3 software[@b32] using a merged reference panel consisting of data from 1000 Genomes Project (phase 1 integrated release 3 March 2012)[@b10] and UK10K (ref. [@b11]). Genotypes were aligned to the positive strand in both imputation and genotyping. Imputation was conducted separately for each study, and in each the data were pruned to a common set of SNPs between cases and controls before imputation. We set thresholds for imputation quality to retain potential risk variants with MAF\>0.005 for validation. Poorly imputed SNPs defined by an information measure \<0.80 were excluded. Tests of association between imputed SNPs and CLL was performed using logistic regression under an additive genetic model in SNPTESTv2.5 (ref. [@b33]). The adequacy of the case--control matching and possibility of differential genotyping of cases and controls were formally evaluated using Q--Q plots of test statistics ([Supplementary Fig. 1](#S1){ref-type="supplementary-material"}). The inflation factor *λ* was based on the 90% least-significant SNPs[@b34]. Where appropriate, principal components, generated using common SNPs, were included in the analysis to limit the effects of cryptic population stratification that otherwise might cause inflation of test statistics. Eigenvectors for the GWAS data sets were inferred using smartpca (part of EIGENSOFT[@b35]) by merging cases and controls with Phase II HapMap samples.

Replication studies and technical validation
--------------------------------------------

The 16 SNPs in the most promising loci were taken forward for *de novo* replication ([Supplementary Table 2](#S1){ref-type="supplementary-material"}). The UK replication series comprised 645 cases collected through the NCLLC and Leicester Haematology Tissue Bank and 2,341 controls comprised 2,780 healthy individuals ascertained through the National Study of Colorectal Cancer (1999--2006; ref. [@b36]). These controls were the spouses or unrelated friends of individuals with malignancies. None had a personal history of malignancy at the time of ascertainment. Both cases and controls were British residents and had self-reported European ancestry. The Mayo replication series comprised 407 newly diagnosed cases and 1,207 clinic-based controls from the Mayo Clinic CLL case--control study[@b37]. The eligibility criteria of the cases were age 20 years and older, consented within 9 months of their initial diagnosis at presentation to Mayo Clinic and no history of HIV. The eligibility criteria for the controls were age 20 years and older, a resident of Minnesota, Iowa or Wisconsin at the time of appointment at Mayo Clinic, no history of lymphoma or leukaemia and no history of HIV infection. Controls were frequency matched to the regional case distribution on 5-year age group, sex and geographic area. *In silico* replication was performed in 444 cases and 609 controls from International Cancer Genome Consortium (ICGC), and 226 cases and 228 controls from the WHI study[@b38][@b39].

The fidelity of imputation as assessed by the concordance between imputed and directly genotyped SNPs was examined in a subset of samples ([Supplementary Table 5](#S1){ref-type="supplementary-material"}). Replication genotyping of UK samples was performed using competitive allele-specific PCR KASPar chemistry (LGC, Hertfordshire, UK); replication genotyping of Mayo samples was performed using Sequenom MassARRAY (Sequenom Inc., San Diego, CA, USA). Primers are listed in [Supplementary Table 9](#S1){ref-type="supplementary-material"}. Call rates for SNP genotypes were \>95% in each of the replication series. To ensure the quality of genotyping in all assays, at least two negative controls and duplicate samples (showing a concordance of \>99%) were genotyped at each centre. To exclude technical artefacts in genotyping, we performed cross-platform validation of 96 samples and sequenced a set of 96 randomly selected samples from each case and control series to confirm genotyping accuracy. Assays were found to be performing robustly; concordance was \>99%.

Meta-analysis
-------------

Meta-analyses were performed using the fixed-effects inverse-variance method based on the *β* estimates and s.e.\'s from each study using META v1.6 (ref. [@b40]). Cochran\'s Q-statistic to test for heterogeneity and the *I*^2^ statistic to quantify the proportion of the total variation due to heterogeneity were calculated[@b41]. Using the meta-analysis summary statistics and LD correlations from a reference panel of the 1000 Genomes Project combined with UK10K we used Genome-wide Complex Trait Analysis to perform conditional association analysis[@b42]. Association statistics were calculated for all SNPs conditioning on the top SNP in each loci showing genome-wide significance. This is carried out in a step-wise manner.

Analysis of exome-sequencing data
---------------------------------

Previously published exome-sequencing data from 141 cases from 66 CLL families[@b43] were interrogated to search for deleterious (missense, nonsense, frameshift or splice site) variants within a genomic interval spanning all SNPs with LD *r*^2^\>0.2 with each index SNP. Positions resulting in protein-altering changes were identified using the Ensembl Variant Effect Predictor (version 78).

Mutational status
-----------------

*IGVH* mutation status was determined according to the BIOMED-2 protocols as described previously[@b44]. Sequence analysis was conducted using the Chromas software version 2.23 (Applied Biosystems) and the international immunogenetics information system database. In accordance with published criteria, we classified sequences with a germline identity of ≥98% as unmutated and those with an identity of \<98% as mutated.

Association between genotype and patient outcome
------------------------------------------------

To examine the relationship between SNP genotype and patient outcome, we analysed two patient series: (1) 356 patients from the UK Leukaemia Research Fund (LRF) CLL-4 trial[@b45], which compared the efficacy of fludarabine, chlorambucil and the combination of fludarabine plus cyclophosphamide; (2) 377 newly diagnosed patients from Mayo Clinic who were prospectively followed. Cox-regression analysis was used to estimate genotype-specific hazard ratios and 95% CIs with overall survival. Statistical analyses were undertaken using R version 2.5.0.

eQTL analysis
-------------

eQTL analyses were performed by examining the gene expression profiles of 452 CLL cases (Affymetrix Human Genome U219 Array)[@b46]. Additional data were obtained by querying publicly available eQTL mRNA expression data using MuTHER[@b47], the Blood eQTL browser[@b48] and data from the GTEx consortium[@b49]. MuTHER contains expression data on LCLs, skin and adipose tissue from 856 healthy twins. The Blood eQTL browser contains expression data from 5,311 non-transformed peripheral blood samples. We used the whole-blood RNA-seq data from GTEx, which consisted of data from 338 individuals.

Functional annotation
---------------------

Novel risk SNPs and their proxies (that is, *r*^2^\>0.2 in the 1000 Genomes EUR reference panel) were annotated for putative functional effect based upon histone mark ChIP-seq/ChIPmentation data for H3K27ac, H3K4Me1 and H3K27Me3 from GM12878 (LCL)[@b18] and primary CLL cells[@b19]. We searched for overlap with 'super-enhancer\' regions as defined by Hnisz *et al*.[@b21], restricting the analysis to the GM12878 cell line and CD19^+^ B cells. We also interrogated ATAC-seq data from CLL cells[@b19] and primary B cells[@b20]. The novel risk SNPs and their proxies (*r*^2^\>0.2 as above) were intersected with regions of accessible chromatin in CLL cells, as defined by Rendeiro *et al*.[@b19], which were used as a surrogate for likely sites of TF binding. SNPs falling within accessible sites (*n*=47) were taken forward to TF-binding motif analysis and were also annotated for genomic evolutionary rate profiling score[@b50] as well as bound TFs based on ENCODE project[@b18] ChIP-seq data.

TF-binding disruption analysis
------------------------------

To determine whether the risk variants or their proxies were disrupting motif-binding sites, we used the motifbreakR package[@b22]. This tool predicts the effects of variants on TF-binding motifs, using position probability matrices to determine the likelihood of observing a particular nucleotide at a specific position within a TF-binding site. We tested the SNPs by estimating their effects on over 2,800 binding motifs as characterized by ENCODE[@b51], FactorBook[@b52], HOCOMOCO[@b53] and HOMER[@b54]. Scores were calculated using the relative entropy algorithm.

TF and histone mark enrichment analysis
---------------------------------------

To examine enrichment in specific TF binding across risk loci, we adapted the variant set enrichment method of Cowper-Sal lari *et al*.[@b23]. Briefly, for each risk locus, a region of strong LD (defined as *r*^2^\>0.8 and *D′*\>0.8) was determined, and these SNPs were termed the associated variant set (AVS). TF ChIP-seq uniform peak data were obtained from ENCODE for the GM12878 cell line, which included data for 82 TF and 11 histone marks. For each of these marks, the overlap of the SNPs in the AVS and the binding sites was determined to produce a mapping tally. A null distribution was produced by randomly selecting SNPs with the same characteristics as the risk-associated SNPs, and the null mapping tally calculated. This process was repeated 10,000 times, and approximate *P*-values were calculated as the proportion of permutations where null mapping tally was greater or equal to the AVS mapping tally. An enrichment score was calculated by normalizing the tallies to the median of the null distribution. Thus, the enrichment score is the number of s.d.\'s of the AVS mapping tally from the mean of the null distribution tallies.

Heritability analysis
---------------------

We used genome-wide complex trait analysis[@b42] to estimate the polygenic variance (that is, heritability) ascribable to all genotyped and imputed GWAS SNPs. SNPs were excluded based on low MAF (MAF\<0.01), poor imputation (info score \<0.4) and evidence of departure from Hardy Weinberg Equilibrium (HWE) (*P*\<0.05). Individuals were excluded for poor imputation and where two individuals were closely related. A genetic relationship matrix of pairs of samples was used as input for the restricted maximum likelihood analysis to estimate the heritability explained by the selected set of SNPs. To transform the estimated heritability to the liability scale, we used the lifetime risk[@b55][@b56] for CLL, which is estimated to be 0.006 by SEER (<http://seer.cancer.gov/statfacts/html/clyl.html>). The variance of the risk distribution due to the identified risk loci was calculated as described by Pharoah *et al*.[@b57], assuming that the relative risk when a first-degree relative has CLL is 8.5 (ref. [@b1]).

Pathway analysis
----------------

To investigate the interaction between the gene products of the GWAS hits, we performed a pathway analysis. We selected the closest coding genes for the lead-associated SNPs and then performed pathway analysis using the LENS tool[@b25], which identifies gene product and protein--protein interactions from HPRD[@b58] and BioGRID[@b59]. Enrichment of pathways was assessed using Fisher\'s exact test, comparing the overlap of the genes in the network with the genes in the pathway. Pathway data were obtained from REACTOME[@b60]. Cytoscape was used to perform network analyses[@b61], and the Hive Plot was drawn using HiveR ([academic.depauw.edu/\~hanson/HiveR/HiveR.html](http://academic.depauw.edu/~hanson/HiveR/HiveR.html)).

Data availability
-----------------

Genotype data that support the findings of this study have been deposited in the database of Genotypes and Phenotypes (dbGAP) under accession code phs000802.v2.p1 and in the European Genome-phenome Archive (EGA) under accession codesEGAS00001000090, EGAD00001000195, EGAS00001000108, EGAD00000000022 and EGAD00000000024.

Transcriptional profiling data from the MuTHER consortium that support the findings of this work have been deposited in the European Bioinformatics Institute (Part of the European Molecular Biology Laboratory, EMBL-EBI) under accession code E-TABM-1140. Data from Blood eQTL have been deposited in the EBI-EMBL under accession codes E-TABM-1036, E-MTAB-945 and E-MTAB-1708. GTEx data are deposited in dbGaP under accession code phs000424.v6.p1. The remaining data are contained within the paper and its Supplementary files or are available from the authors upon reasonable request.
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![Manhattan plot of association *P* values.\
Shown are the genome-wide *P* values (two-sided) of \>10 million successfully imputed autosomal SNPs in 4,478 cases and 13,213 controls from the discovery phase. Text labelled in red are previously identified risk loci, and text labelled in blue are newly identified risk loci. The red horizontal line represents the genome-wide significance threshold of *P*=5.0 × 10^−8^.](ncomms14175-f1){#f1}

![Regional plots of association results and recombination rates for new risk loci for chronic lymphocytic leukaemia.\
Results shown for 1p36.11, 4q24, 4q35.1, 19p13.3, 22q13.33 (**a**--**e**). Plots (drawn using visPig[@b62]) show association results of both genotyped (triangles) and imputed (circles) SNPs in the GWAS samples and recombination rates. −log~10~ *P* values (*y* axes) of the SNPs are shown according to their chromosomal positions (*x* axes). The sentinel SNP in each combined analysis is shown as a large circle or triangle and is labelled by its rsID. The colour intensity of each symbol reflects the extent of LD with the top genotyped SNP, white (*r*^2^=0) through to dark red (*r*^2^=1.0). Genetic recombination rates, estimated using the 1000 Genomes Project samples, are shown with a light blue line. Physical positions are based on NCBI build 37 of the human genome. Also shown are the chromatin-state segmentation track (ChromHMM) for lymphoblastoid cells using data from the HapMap ENCODE Project, and the positions of genes and transcripts mapping to the region of association.](ncomms14175-f2){#f2}

![Regional plots of association results and recombination rates for new risk loci for chronic lymphocytic leukaemia.\
Results shown for 1q42.13, 6p21.31, 11q23.2, 18q21.1 (**a**--**d**). Plots (drawn using visPig[@b62]) show association results of both genotyped (triangles) and imputed (circles) SNPs in the GWAS samples and recombination rates. −log~10~ *P* values (*y* axes) of the SNPs are shown according to their chromosomal positions (*x* axes). The sentinel SNP in each combined analysis is shown as a large circle or triangle and is labelled by its rsID. The colour intensity of each symbol reflects the extent of LD with the top genotyped SNP, white (*r*^2^=0) through dark red (*r*^2^=1.0). Genetic recombination rates, estimated using the 1000 Genomes Project samples, are shown with a light blue line. Physical positions are based on NCBI build 37 of the human genome. Also shown are the chromatin-state segmentation track (ChromHMM) for lymphoblastoid cells using data from the HapMap ENCODE Project, and the positions of genes and transcripts mapping to the region of association.](ncomms14175-f3){#f3}

![Enrichment of transcription factors and histone marks.\
The enrichment and over-representation of (**a**) histone marks and (**b**) transcription factors using the new risk SNPs and known CLL risk SNPs. The red line represents the Bonferroni-corrected *P* value threshold.](ncomms14175-f4){#f4}

![Hive Plot of common protein--protein interactions in CLL.\
Each arm represents a functional annotation term, each arc represents an interaction between two proteins and the distance from the centre of the plot corresponds to a greater number of protein--protein interactions (higher degree of the node). The left arm represents proteins annotated as being involved in BCR signalling; the top arm represents proteins annotated as immune response; the right arm represents proteins involved in apoptosis; and the bottom arm represents proteins involved in DNA damage and chromosomal integrity. Selected proteins known to be involved in CLL risk are shown.](ncomms14175-f5){#f5}

###### Summary results for SNPs associated with CLL risk.

  **SNP**       **Locus**   **Position (bp, hg19)**   **Risk allele**   **Data set**   **RAF (case; control)**    **OR**       **95% CI**      ***P*** **value**
  ------------ ----------- ------------------------- ----------------- -------------- ------------------------- ---------- ------------------ --------------------
  rs34676223     1p36.11           23943735                  C           Discovery          (0.74; 0.71)           1.16       (1.09; 1.22)       2.69 × 10^−7^
                                                                        Replication         (0.74; 0.69)           1.29       (1.18; 1.42)       4.69 × 10^−8^
                                                                          Combined                               **1.19**   **(1.14; 1.25)**   **5.04 × 10**^−13^
                                                                                                                              *I*^2^*=*24%      *P*~het~*=*0.23
                                                                                                                                                        
  rs41271473     1q42.13           228880296                 G           Discovery          (0.81; 0.79)           1.19       (1.12; 1.26)       4.69 × 10^−8^
                                                                        Replication         (0.82; 0.79)           1.20       (1.08; 1.34)       5.59 × 10^−4^
                                                                          Combined                               **1.19**   **(1.13; 1.26)**   **1.06 × 10**^−10^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.95
                                                                                                                                                        
  rs71597109      4q24             102741002                 C           Discovery          (0.72; 0.69)           1.17       (1.11; 1.24)       1.02 × 10^−8^
                                                                        Replication         (0.73; 0.71)           1.15       (1.05; 1.26)       3.46 × 10^−3^
                                                                          Combined                               **1.17**   **(1.11; 1.22)**   **1.37 × 10**^−10^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.78
                                                                                                                                                        
  rs57214277     4q35.1            185254772                 T           Discovery          (0.44; 0.41)           1.14       (1.08; 1.19)       9.56 × 10^−7^
                                                                        Replication         (0.43; 0.39)           1.12       (1.03; 1.21)           0.011
                                                                          Combined                               **1.13**   **(1.08; 1.18)**   **3.69 × 10**^−8^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.53
                                                                                                                                                        
  rs3800461      6p21.31           34616322                  C           Discovery          (0.13; 0.11)           1.21       (1.12; 1.31)       4.20 × 10^−7^
                                                                        Replication         (0.12; 0.11)           1.17       (1.03; 1.34)           0.014
                                                                          Combined                               **1.20**   **(1.13; 1.28)**   **1.97 × 10**^−8^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.69
                                                                                                                                                        
  rs61904987     11q23.2           113517203                 T           Discovery          (0.14; 0.12)           1.23       (1.14; 1.32)       4.44 × 10^−8^
                                                                        Replication         (0.13; 0.12)           1.26       (1.12; 1.42)       1.20 × 10^−4^
                                                                          Combined                               **1.24**   **(1.16; 1.32)**   **2.46 × 10**^−11^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.83
                                                                                                                                                        
  rs1036935      18q21.1           47843534                  A           Discovery          (0.25; 0.22)           1.17       (1.10; 1.24)       2.81 × 10^−7^
                                                                        Replication         (0.24; 0.22)           1.11       (1.01; 1.23)           0.028
                                                                          Combined                               **1.15**   **(1.10; 1.21)**   **3.27 × 10**^−8^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.65
                                                                                                                                                        
  rs7254272      19p13.3            4069119                  A           Discovery          (0.20; 0.18)           1.18       (1.11; 1.26)       4.61 × 10^−7^
                                                                        Replication         (0.19; 0.18)           1.13       (1.01; 1.26)           0.026
                                                                          Combined                               **1.17**   **(1.10; 1.23)**   **4.67 × 10**^−8^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.55
                                                                                                                                                        
  rs140522      22q13.33           50971266                  T           Discovery          (0.35; 0.32)           1.16       (1.10; 1.22)       2.20 × 10^−8^
                                                                        Replication         (0.35; 0.33)           1.10       (1.01; 1.2)            0.025
                                                                          Combined                               **1.15**   **(1.10; 1.20)**   **2.70 × 10**^−9^
                                                                                                                              *I*^2^*=*0%       *P*~het~*=*0.94

bp, base pair position; CLL, chronic lymphocytic leukaemia; *I*^2^, proportion of the total variation due to heterogeneity; OR, odds ratio; *P*~het~, *P*-value for heterogeneity; RAF, risk allele frequency; SNP, single-nucleotide polymorphism; 95% CI, 95% confidence interval.

RAF is risk allele frequency across all of the discovery and replication data sets, respectively. ORs are derived with respect to the risk allele. Text in bold highlight the *P*-value in the combined data.
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